| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H44O2 |
| Molecular Weight | 400.6371 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C3/C[C@@H](O)C[C@H](O)C3=C
InChI
InChIKey=OFHCOWSQAMBJIW-AVJTYSNKSA-N
InChI=1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1
| Molecular Formula | C27H44O2 |
| Molecular Weight | 400.6371 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
Alfacalcidol (1-hydroxyvitamin D3) is a synthetic analog of vitamin D introduced clinically in the early 1970s. A prodrug for calcitriol (1,25-dihydroxyvitamin D3), it is one of the most potent and rapidly acting compounds currently used in the prevention and treatment of vitamin D deficiency states and hypocalcemia. The clinical benefit of alfacalcidol is related to the stimulation of calcium and phosphorus absorption, reversal of myopathy, promotion of mineralization in bone and the ability to reabsorb fully mineralized bone. Similar marketed vitamin D compounds include calcitriol and ergocalciferol. Alfacalcidol is indicated in conditions where there is a disturbance of calcium metabolism due to impaired 1-α hydroxylation such as when there is reduced renal function.
Approval Year
Cmax
AUC
T1/2
Doses
AEs
Sample Use Guides
Initial dose for all indications:
Adults: 1 microgram/day
Dosage in the elderly: 0.5 microgram/day
Neonates and premature infants: 0.05 – 0.1 microgram/kg/day
Children under 20kg bodyweight: 0.05 microgram/kg/day
Children over 20kg bodyweight: 1 microgram/day
Route of Administration:
Oral
